2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3307 Allogeneic anti-CD19 CAR T-cell therapy followed by olverembatinib maintenance in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Wenzhi CAI, MD, Yiyan Zhu2, Ling Zhang3, Mengqian Chu4, Yuanyuan Du5, Fei Zhou, MD6, Ailing Deng7, Jia Yin, MD, PhD8, Jing Lu, MD9, Xuefeng He10, Yuejun Liu11, Qian Wu12, Depei Wu Sr, MD13, Suning Chen14
1 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
2 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
3 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
4 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
5 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
6 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
7 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
8 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
9 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
10 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
11 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
12 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
13 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
14 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China

Introduction:

Third-generation tyrosine kinase inhibitors and blinatumomab have substantially improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); however, the role of chimeric antigen receptor (CAR) T-cell therapy in the frontline setting remains under investigation. We evaluated a novel transplantation-free strategy comprising a single infusion of the allogeneic anti-CD19 CAR T-cell product ThisCART19A followed by olverembatinib maintenance in adults with newly diagnosed Ph+ ALL.

Methods:

This single-center, single-arm, phase 2 study was conducted at the First Affiliated Hospital of Soochow University and registered at ClinicalTrials.gov (NCT07074496). Patients received one week of pretreatment with vindesine and dexamethasone, followed by fludarabine- and cyclophosphamide-based lymphodepletion and a single infusion of the allogeneic anti-CD19 CAR T-cell product ThisCART19A at a dose of 3 × 106 cells/kg. Patients who achieved complete remission (CR) on day 28 subsequently received single-agent olverembatinib maintenance. The primary endpoint was the proportion of patients achieving complete molecular response (CMR) at 3 months after ThisCART19A infusion, with CMR defined as undetectable bone marrow BCR::ABL1 transcripts by quantitative reverse-transcription polymerase chain reaction. Patients were enrolled between December 2023 and September 2025, and the data cutoff was July 31, 2026.

Results:

Seventeen patients were screened, of whom 16 received ThisCART19A infusion. The median age was 32 years (range, 18–64 years). On day 28, all 16 patients achieved CR; 11/16 (68.8%) achieved flow cytometry-based measurable residual disease (FCM-MRD) negativity, 10/16 (62.5%) achieved CMR, and 2/16 (12.5%) achieved a major molecular response (MMR). At 3 months, 14/16 patients (87.5%) achieved CMR, meeting the primary endpoint; 13/16 (81.3%) were FCM-MRD negative, 1/16 (6.3%) remained in MMR, and 1/16 (6.3%) had relapsed. Among 14 evaluable patients, 11 (78.6%) achieved immunoglobulin/T-cell receptor gene rearrangement–based MRD (IG/TR-MRD) negativity. At 6 months, all 15 evaluable patients were FCM-MRD negative, 14/15 (93.3%) were in CMR, 1/15 (6.7%) remained in MMR, and 12/13 evaluable patients (92.3%) were IG/TR-MRD negative. At the data cutoff, all 15 evaluable patients remained FCM-MRD negative; 14/15 (93.3%) were in CMR, and 1/15 (6.7%) remained in MMR. All 13 patients evaluable for IG/TR-MRD were negative. No additional relapses occurred, and the remaining 15 patients maintained ongoing deep responses. At a median follow-up of 11.0 months (range, 9.5–30.9 months), the 1-year event-free survival (EFS) and overall survival (OS) rates were 93.8% (95% CI, 63.2%–99.1%) and 100%, respectively. Following infusion, rapid peripheral B-cell depletion, early CAR T-cell expansion, and transient increases in inflammatory biomarkers were observed. Cytokine release syndrome (CRS) occurred in 15/16 patients, including grade 3 CRS in 4/16 (25.0%). Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 3/16 patients, including one grade 3 event. No grade 4 CRS or ICANS occurred, and no clinically significant graft-versus-host disease was observed during follow-up.

Conclusion:

In this small frontline cohort, a single ThisCART19A infusion followed by single-agent olverembatinib maintenance induced rapid and deep molecular responses, with encouraging early disease control and a manageable toxicity profile. These findings support further evaluation of this approach as a potential transplantation-free management strategy for adults with newly diagnosed Ph+ ALL.

Wenzhi CAI, MD: No relevant conflicts of interest to declare.